Interestingly, recent studies have validated PLK1 as a potential target to improve the efficacy of immunotherapies in lung cancer [20], consistent with our findings in pancreatic cancer that targeting PLK1 enhances the effectiveness of immune checkpoint blockade [21]. The gene discussed is PLK1; the disease is lung cancer.